Korean J Ophthalmol.  2012 Apr;26(2):139-142. 10.3341/kjo.2012.26.2.139.

Intravitreal Bevacizumab for Treatment of Refractory Central Serous Choroidoretinopathy

• Entezari M
• Ramezani A
• Yaseri M

• KMID: 1364869
• DOI: http://doi.org/10.3341/kjo.2012.26.2.139

Abstract

In a clinical case series, 5 patients with not-resolved central serous choroidoretinopathy (CSC) lasting more than 1 year received one intravitreal bevacizumab injection (IVB, 1.25 mg) injection. All patients underwent a through ophthalmic examination 1 day, 1 week, and 1, 2, and 6 months after the injection. Best corrected visual acuity (BCVA) and central macular thickness were compared before and after treatment by optical coherence tomography. Mean BCVA was improved significantly (p = 0.020) from 0.60 +/- 0.25 to 0.50 +/- 0.18 and 0.29 +/- 0.19 logarithm of minimum angle of resolution at 6 and 18 weeks, respectively. Central macular thickness was also decreased significantly (p = 0.010) from 370 +/- 65 to 208 +/- 23 microm at 4 months. No recurrence was occurred during follow-up. IVB injection may have beneficial effect in the treatment of refractory CSC.

Keyword

Bevacizumab; Central serous choroidoretinopathy; Optical coherence tomography

MeSH Terms

Adult
Angiogenesis Inhibitors/*administration & dosage
Antibodies, Monoclonal, Humanized/*administration & dosage
Central Serous Chorioretinopathy/*drug therapy/*pathology
Female
Follow-Up Studies
Humans
Intravitreal Injections
Male
Middle Aged
Tomography, Optical Coherence
Treatment Outcome
Visual Acuity/drug effects

Figure

• 

  Fig. 1 OCT pictures of 4 cases before and after treatment by IVB showing nearly complete (cases 1 [A], 2 [B], and 3 [C]) and partial (cases 4 [D] and 5 [E]) resolutions of subretinal fluid.

Reference

1. Wang M, Munch IC, Hasler PW, et al. Central serous chorioretinopathy. Acta Ophthalmol. 2008. 86:126–145.

2. Marmor MF, Tan F. Central serous chorioretinopathy: bilateral multifocal electroretinographic abnormalities. Arch Ophthalmol. 1999. 117:184–188.

3. Burumcek E, Mudun A, Karacorlu S, Arslan MO. Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology. 1997. 104:616–622.

4. Spitznas M. Pathogenesis of central serous retinopathy: a new working hypothesis. Graefes Arch Clin Exp Ophthalmol. 1986. 224:321–324.

5. Marmor MF. New hypotheses on the pathogenesis and treatment of serous retinal detachment. Graefes Arch Clin Exp Ophthalmol. 1988. 226:548–552.

6. Cardillo Piccolino F, Eandi CM, Ventre L, et al. Photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2003. 23:752–763.

7. Torres-Soriano ME, Garcia-Aguirre G, Kon-Jara V, et al. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol. 2008. 246:1235–1239.

8. Von Graefe A. Ueber centrale recidivierende retinitis. Graefes Arch Clin Exp Ophthalmol. 1866. 12:211–215.

9. Schaal KB, Hoeh AE, Scheuerle A, et al. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol. 2009. 19:613–617.

10. Chan WM, Lam DS, Lai TY, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003. 87:1453–1458.

11. Battaglia Parodi M, Da Pozzo S, Ravalico G. Photodynamic therapy in chronic central serous chorioretinopathy. Retina. 2003. 23:235–237.

12. Ober MD, Yannuzzi LA, Do DV, et al. Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology. 2005. 112:2088–2094.

13. Colucciello M. Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy. Retina. 2006. 26:239–242.